Spinal Muscular Atrophy Treatment and Outcomes

This webinar will provide an overview of the U.S. Food and Drug Administration (FDA) approved therapies for Spinal Muscular Atrophy (SMA), the pros and cons of each therapy, physician's experiences with these therapies, and long-term issues regarding treatment and outcomes. Please note that the purpose of this webinar is strictly for information dissemination and discussion; APHL does not endorse any specific therapy or treatment.

Audience: Individuals responsible for screening, diagnosing, and treating SMA.

Moderators: 

• Amy Gaviglio, MS, LCGC, Co-Chair, APHL, NewSTEPs New Disorders Workgroup

• George Dizikes, PhD, HCLD/CC (ABB), Co-Chair, APHL, NewSTEPs Disorders Workgroup

Speakers:

• Jennifer Kwon, MD, CGC, Faculty, University of Wisconsin School of Medicine and Public Health

• Russell Butterfield, MD, PhD, Department of Neurology and Pediatrics, University of Utah

• Melissa Gibbons, MS, CGC, Genetic Counselor, Children's Hospital Colorado,

• Julie Parsons, MD, Co-Director, Neuromuscular Clinic, Children's Hospital Colorada